Theratechnologies Inc T.TH

PFE buys TRIL

[Scioto1]

PFE announced buyout of TRIL an $800 m cancer drug company for about $2.3 b. TRIL Stock is at $18/share, up from $6.

[archeo753]

If TH has any success with cancer there will be offers coming.  The way Paul has been hiring lately though it looks like he is in for the long term and not looking to sell.  Feeling goood about holding TH until we see some results from PH 1.

[muslix1]

18US $ i am out... for 13 years i have been waiting for the BIG day...

[FredTheVoice]

Good to see that you are still here ! In 2021 or 2022 ? If cancer is positive, well, 30$C is something realistic. Lets see. FTV.

[Wino115]

According to Barclays, the average SMID Cap oncology takeover multiple over the last 5 years is at 9.8x 5 years estimated revenues, and 90% premium to stock price. That does not include today's which was a 200% premium to the stock price.

[Scioto1]

Good perspective. Thanks Wino!

[Wino115]

This valuation multiple shows the importance of gaining indications for ALL solid tumors over expressing sortilin. It's a muti-market revenue model -- far better than what, say, Trodelvy has now. Today's takeover is in the leukemia area. It the FDA allows them to run with the "All Sortilin Expressing Solid Tumors", that would be massive. I have no clue if they grant broad INDs

[scarlet1967]

The master protocols allow the sponsor to use single drug for various indications which seems to be what the FDA encourage companies with the right drug for the right indication peruse. My read is based on string results the sub-studies can each be approved for their indication. “A Basket Trial involves a single investigational drug or drug combination that is studied across multiple cancer

[qwerty22]

When I researched this there were two examples of multi-indication approvals. Both are based on specific genetic features. One a drug (forgot name) which targets a specific mutation in multiple solid tumours. The other is Keytruda for MSI-H genotypes in solid tumours, again a type of particular mutation pattern. I guess it's possible to move forward with all-SORT but it seems much more likely

[qwerty22]

There is some positivity in biotech today, XBI is up a nice amount. It can't be all on the back of this deal but plenty of positive stuff being said about biotech with this deal. "A 200% premium acquisition of a down and out mid-small cap is EXACTLY what biotech needed. More please!"